<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111045</url>
  </required_header>
  <id_info>
    <org_study_id>09-OA-002</org_study_id>
    <nct_id>NCT01111045</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee</brief_title>
  <official_title>A Phase 2, Double Blind, Randomized, Placebo-Controlled, Proof of Concept, Dose Finding Study of Intraarticular Bone Morphogenetic Protein (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to evaluate the safety and efficacy of intraarticular BMP-7
      for the treatment of osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale.</measure>
    <time_frame>Baseline, and at 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.03 mg/ml BMP-7, single intraarticular knee injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/ml BMP-7, single intraarticular knee injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3 mg/ml BMP-7, single intraarticular knee injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 ml placebo, single intraarticular knee injection (control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bone morphogenetic protein 7</intervention_name>
    <description>Comparison of different doses of the drug via single intraarticular knee injection</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory with a diagnosis of OA of the knee with symptoms for at least 6 months and
             pain on the majority of days in the last 30 days. Symptoms must include knee joint
             pain.

          -  A male or female adult age &gt;40 years

          -  female subjects of childbearing potential must have a negative serum pregnancy test
             during screening and a negative urine pregnancy test on the day of injection

          -  Radiographic evidence of at least one tibiofemoral osteophyte and Osteoarthritis
             Research Society International (OARSI) Atlas joint space narrowing grade of 1 or 2 in
             the index knee

          -  WOMAC pain score of &gt;8 at screening and baseline

          -  Able to comply with the study and give informed consent

          -  Able to read, write and understand English

        Exclusion Criteria:

          -  A requirement for treatment with opioids for pain relief.

          -  Unwilling to abstain from NSAIDs and/or other analgesic medications for 48 hours and
             acetaminophen for 24 hours prior to pain assessments during the study. Subjects taking
             low dose aspirin for cardiovascular health may remain on their stable dose throughout
             the study.

          -  Using a handicap assistance device (i.e., cane, walker) &gt;50% of the time.

          -  Undergoing new physical therapy or participating in a weight loss or exercise program
             that has not been stable for at least 3 months prior to screening visit 1 and will not
             remain stable during their participation in the study.

          -  History of arthroscopic or open surgery to the index knee in the past 12 months or
             planned surgery during study.

          -  History of joint replacement surgery (index knee).

          -  Received corticosteroid, short acting hyaluronic acid, or other intraarticular
             injections of the index knee within 3 months of screening and/or not willing to
             abstain from treatments for the duration of the study

          -  Received long acting hyaluronic acid injection of the index knee within 6 months of
             screening and/or not willing to abstain from treatments for the duration of the study.

          -  History in the past 10 years of reactive arthritis, rheumatoid arthritis, psoriatic
             arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel
             disease, sarcoidosis, amyloidosis or fibromyalgia.

          -  Clinical signs and symptoms of active knee infection or radiographic evidence of
             crystal disease other than chondrocalcinosis (i.e., gout and CPPD).

          -  A history of abnormal laboratory results ≥2.5 x ULN indicative of any significant
             medical disease, which in the opinion of the investigator, would preclude the subjects
             participation in the study

          -  Any of the following abnormal laboratory results during screening:

               1. ALT and AST ≥2.5x ULN

               2. Hemoglobin &lt;11.5 g/dL (Female) or &lt;13.2 g/dL (Male)

               3. WBC &lt;3500 cells/mm3

               4. Lymphocyte count ≤1000 cells/mm3

               5. Serum creatinine ≥1.5 x ULN

               6. Platelet count below the central laboratory lower limit of normal.

          -  History of malignancy in the past ten years (&lt;10 years), with the exception of
             resected basal cell, squamous cell of the skin, resected cervical atypia or carcinoma
             in situ.

          -  Significant hip pain, ipsilateral to the index knee that may interfere with
             assessments of index knee pain

          -  Skin breakdown at the knee where the injection would take place

          -  A known or clinically suspected infection with human immunodeficiency virus (HIV), or
             hepatitis C or B viruses

          -  Participated within 3 months or will participate concurrently in another
             investigational drug or vaccine study

          -  A history of drug or alcohol dependence or abuse in the past 3 years

          -  Previous treatment with BMP-7 or any bone morphogenetic protein

          -  A female with reproductive capability who is unwilling to use birth control for the
             duration of the study and/or intends to conceive within 12 months of dosing.

          -  Other serious, non-malignant, significant, acute or chronic medical or psychiatric
             illness that, in the judgment of the investigator, could compromise subject safety,
             limit the subject's ability to complete the study, and/or compromise the objectives of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Research</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Arthritis Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center, Center for Aging</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robin Dore, MD, Inc</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulder Medical Center, PC</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of S. Florida</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Center for Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Medical Research, AMR, Inc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Bone and Joint Institute</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein &amp; Associates, MD, PA</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Center of Maryland</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research, PC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David R. Mandel, MD, Inc.</name>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Medical Research Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tacoma Center for Arthritis Research</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

